Gushengtang Holdings Limited (HK:2273)
:2273
Want to see HK:2273 full AI Analyst Report?
Top Page
Gushengtang Holdings Limited
(2273)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$31.00
▲(6.90% Upside)
Action:ReiteratedDate:11/08/25
The overall stock score of 68 for Gushengtang Holdings Limited is primarily driven by its strong financial performance (score: 81), reflecting robust revenue growth and solid profitability. However, the score is tempered by weak technical indicators (score: 45), which signal a bearish trend with the stock trading below key moving averages. Valuation (score: 70) remains reasonable, supporting a balanced outlook. Investors should weigh financial strengths against current market momentum risks.
Positive Factors
Revenue Growth
Strong revenue growth indicates expanding market reach and product demand, supporting long-term business sustainability and competitiveness.
Negative Factors
Cash Flow Transparency
Lack of recent cash flow data adds uncertainty, potentially hindering accurate assessment of cash generation and financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates expanding market reach and product demand, supporting long-term business sustainability and competitiveness.
Read all positive factors
Gushengtang Holdings Limited (2273) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.02B
Dividend Yield2.61%
Average Volume (3M)1.54M
Price to Earnings (P/E)7.5
Beta (1Y)1.18
Revenue Growth7.60%
EPS Growth17.41%
CountryHK
Employees2,915
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.12
Shares Outstanding234,371,050
10 Day Avg. Volume1,228,922
30 Day Avg. Volume1,539,754
Financial Highlights & Ratios
PEG Ratio1.38
Price to Book (P/B)3.36
Price to Sales (P/S)2.64
P/FCF Ratio22.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$37.31Price Target Upside28.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.79
Revenue Forecast (FY)HK$3.76B
Gushengtang Holdings Limited Business Overview & Revenue Model
Company Description
Gushengtang Holdings Limited, an investment holding company, provides healthcare services and sells healthcare products. It also engages in the wholesale and retail of pharmaceutical products; and provision of investment management and supply chai...
How the Company Makes Money
Gushengtang Holdings Limited generates revenue primarily through the sale of its herbal products and health supplements. The company employs a multi-channel distribution strategy, selling its products through retail outlets, e-commerce platforms, ...
Gushengtang Holdings Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.15B | 3.02B | 2.32B | 1.62B | 1.37B | 925.37M |
| Gross Profit | 965.99M | 909.35M | 700.00M | 499.54M | 620.30M | 437.49M |
| EBITDA | 444.57M | 375.05M | 429.90M | 324.22M | -62.75M | 119.11M |
| Net Income | 351.56M | 306.78M | 252.20M | 180.85M | -507.07M | -255.75M |
Balance Sheet | ||||||
| Total Assets | 3.89B | 3.66B | 3.38B | 2.61B | 2.39B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 1.24B | 1.14B | 1.33B | 1.02B | 1.03B | 357.33M |
| Total Debt | 639.75M | 508.56M | 370.57M | 351.29M | 345.37M | 870.46M |
| Total Liabilities | 1.51B | 1.28B | 1.07B | 891.49M | 842.39M | 2.58B |
| Stockholders Equity | 2.38B | 2.38B | 2.30B | 1.72B | 1.55B | -1.13B |
Cash Flow | ||||||
| Free Cash Flow | 507.38M | 361.77M | 332.41M | 244.02M | 138.03M | 136.31M |
| Operating Cash Flow | 607.89M | 452.37M | 410.14M | 281.00M | 187.75M | 154.90M |
| Investing Cash Flow | -407.45M | -267.37M | -263.61M | -178.36M | -48.95M | -117.47M |
| Financing Cash Flow | -213.70M | -375.19M | 157.50M | -138.08M | 638.57M | 76.20M |
Gushengtang Holdings Limited Technical Analysis
Neutral
29.00
Price Trends
28.00
Negative
28.78
Negative
30.63
Negative
Market Momentum
0.07
Negative
52.90
Neutral
88.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2273, the sentiment is Neutral. The current price of 29 is above the 20-day moving average (MA) of 27.19, above the 50-day MA of 28.00, and below the 200-day MA of 30.63, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 52.90 is Neutral, neither overbought nor oversold. The STOCH value of 88.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2273.
Gushengtang Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$672.13M | 2.28 | 5.29% | 9.14% | -1.48% | 549.60% | |
68 Neutral | HK$7.02B | 7.50 | 15.36% | 2.61% | 7.60% | 17.41% | |
67 Neutral | HK$1.40B | 5.35 | 18.05% | 4.37% | -4.23% | 3.95% | |
66 Neutral | HK$5.27B | 18.12 | 33.08% | 1.97% | 16.70% | 38.98% | |
62 Neutral | HK$7.37B | 43.03 | 0.62% | ― | -9.81% | -72.54% | |
52 Neutral | HK$1.67B | 117.78 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2273
Gushengtang Holdings Limited
30.34
-0.84
-2.69%
HK:1526
Rici Healthcare Holdings Ltd.
0.88
-0.09
-9.28%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
21.46
5.15
31.58%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.04
0.25
13.97%
HK:3886
Town Health International Medical Group Ltd.
0.24
0.00
0.00%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
11.83
-2.41
-16.92%
Gushengtang Holdings Limited Corporate Events
Gushengtang Expands TCM Services with DA ZHONG TANG Acquisition
Nov 16, 2025
Gushengtang Holdings Limited announced the acquisition of DA ZHONG TANG, a Singapore-based company providing traditional Chinese medicine services and pharmaceutical retail. This acquisition aligns with Gushengtang’s strategy to expand its o...
Gushengtang Holdings Limited Announces Share Repurchase to Boost Shareholder Value
Nov 6, 2025
Gushengtang Holdings Limited has announced a voluntary share repurchase initiative under a previously granted mandate, allowing the company to buy back up to 10% of its issued shares. The board has approved an additional HK$300 million for the rep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.